{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "OIG Reports on Impact of “High-Priced Drugs” on Medicare Part D Catastrophic Coverage Spending",
    "url": "https://www.lexblog.com/2017/01/30/oig-reports-on-impact-of-high-priced-drugs-on-medicare-part-d-catastrophic-coverage-spending/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-EF4RMDM7",
        "url": "https://www.lexblog.com/lib/EF4RMDM7/"
    },
    "datePublished": "2017-01-30T05:17:15-05:00",
    "dateModified": "2022-07-22T17:09:51-04:00",
    "author": {
        "@type": "Person",
        "name": "Debra A. McCurdy, Brenda Boschetto"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Reed Smith LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Health Industry Washington Watch",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.healthindustrywashingtonwatch.com/?p=16582",
    "sourceStability": "may-move"
}